Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Multi-center randomized controlled clinical trial, We intended to recruit the participants
who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to
receive the third dose of vaccine (inactivated vaccine, or recombinant subunit protein
vaccine and mRNA vaccine) into the experimental group, and the participants who completed 2
doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination
plan into the control group. Participants in the experimental group received the third dose
of SARS-CoV-2 vaccination at baseline, and participants in the control group received no
intervention. Each subject will be followed up for one year after enrollment, and
neutralizing antibodies and total antibodies will be tested at the specified time points, as
well as the records of adverse events and adverse reactions.
The study set up 4 groups, 100 people each for inactivated vaccine, recombinant subunit
protein vaccine, mRNA vaccine and the control group, totaling 400 people.